ArticleBMC biotechnology2025
Staphylococcus epidermidis MB614 and Staphylococcus hominis MB621 from human milk as up regulators of TNF-α induced IL-8 production by Caco-2 cell line.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast milk harbors many bacteria that shape the newborn microbiota. The present study aimed to investigate the immunomodulatory properties of bacteria from selected Pakistani mother’s breast milk samples. The probiotic strains studied are associated with immune modulation in intestinal epithelial cells, showing potential probiotic properties to be used in a simulated human milk formula. Identification was carried out through 16 S rRNA gene sequencing, which revealed the presence of 50% diversity of Staphylococcus hominis and 35% of Staphylococcus epidermidis among all the isolates. Probiotic bacteria are considered to protect the gastrointestinal tract (GIT) by adhering to the gut epithelial cells and reducing the population of pathogens. The cytotoxicity of Staphylococcus hominis MB614 and Staphylococcus epidermidis MB621 against epithelial cells was tested by co-culturing the strains with Caco-2 cells. Tested probiotic bacteria at concentrations, 1 × 106, to 1 × 102 CFU/ml for 24 h exhibited no noticeable cytotoxic effect on Caco-2 cells. Staphylococcus hominis MB614 and Staphylococcus epidermidis MB621 were examined for modulation of the immune system in human colon carcinoma cell lines (Caco-2) after the effect of the proinflammatory cytokine tumour necrosis factor α (TNF-α) by regulating the proinflammatory interleukin 8 (IL-8). Staphylococcus hominis MB614 and Staphylococcus epidermidis MB621 regulate TNF-α induced IL-8 production in a time-dependent manner. In conclusion, Staphylococcus hominis MB614 and Staphylococcus epidermidis MB621, isolated from human milk, when administered in sufficient amounts and for a certain duration, may be used to modulate inflammation inside the colon by up-regulating the production of IL-8, potentially enhancing innate immunity. This study with these probiotics suggested the modulation of the immune system and disease prevention in the human body.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.